IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer

Jemal, 2009, Cancer statistics, CA. Cancer. J. Clin., 59, 225, 10.3322/caac.20006 Bokhman, 1983, Two pathogenetic types of endometrial carcinoma, Gynecol. Oncol., 15, 10, 10.1016/0090-8258(83)90111-7 Lax, 2004, Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification, Virchows Arch., 444, 213, 10.1007/s00428-003-0947-3 Goff, 1994, Uterine papillary serous carcinoma: patterns of metastatic spread, Gynecol. Oncol., 54, 264, 10.1006/gyno.1994.1208 Hamilton, 2006, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers, Br. J. Cancer., 94, 642, 10.1038/sj.bjc.6603012 Boruta, 2004, Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?, Cancer, 101, 2214, 10.1002/cncr.20645 Salvesen, 2012, Markers for individualised therapy in endometrial carcinoma, Lancet Oncol., 13, e353, 10.1016/S1470-2045(12)70213-9 Banno, 2012, Biomarkers in endometrial cancer: possible clinical applications (Review), Oncol. Lett., 3, 1175, 10.3892/ol.2012.654 Pallares, 2004, Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma, J. Pathol., 204, 569, 10.1002/path.1666 LeRoith, 1995, Molecular and cellular aspects of the insulin-like growth factor I receptor, Endocrine Rev., 16, 143, 10.1210/edrv-16-2-143 Baserga, 1997, The IGF-I receptor in cell growth, transformation and apoptosis, Biochim. Biophys. Acta., 1332, F105 Werner, 2003, The molecular basis of IGF-I receptor gene expression in human cancer, 346 Werner, 2003, The IGF-I receptor gene: a molecular target for disrupted transcription factors, Gene Chromosomes Cancer, 36, 113, 10.1002/gcc.10157 Werner, 2006, The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action, Trends Endocrinol. Metab., 17, 236, 10.1016/j.tem.2006.06.007 Khandwala, 2000, The effects of insulin-like growth factors on tumorigenesis and neoplastic growth, Endocrine Rev., 21, 215, 10.1210/er.21.3.215 McCampbell, 2006, Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium, Clin. Cancer Res., 12, 6373, 10.1158/1078-0432.CCR-06-0912 Pengchong, 2011, Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma, Eur. J. Gynaecol. Oncol., 32, 660 Werner, 2009, The insulin-like growth factor-I receptor as an oncogene, Arch. Physiol. Biochem., 115, 58, 10.1080/13813450902783106 Atzori, 2011, A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors, Clin. Cancer Res., 17, 6304, 10.1158/1078-0432.CCR-10-3336 Brasaemle, 1988, Microelisa reader quantitation of fixed, stained, solubilized cells in microtitre dishes, Biotechniques, 6, 418 Attias-Geva, 2011, Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells, Eur. J. Cancer., 47, 1717, 10.1016/j.ejca.2011.02.019 Duriez, 1997, Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death, Biochem. Cell Biol. [Biochimie et biologie cellulaire], 75, 337, 10.1139/o97-043 Bruchim, 2009, Targeting the IGF1 axis in cancer proliferation, Expert Opin. Ther. Targets., 13, 1179, 10.1517/14728220903201702 Ayabe, 1997, Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer, Endocr. J., 44, 419, 10.1507/endocrj.44.419 Petridou, 2003, Endometrial cancer and the IGF system: a case-control study in Greece, Oncology, 64, 341, 10.1159/000070291 Gunter, 2008, A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer, Cancer Epidemiol. Biomarkers Prev., 17, 921, 10.1158/1055-9965.EPI-07-2686 Hirano, 2004, Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers, Eur. J. Gynaecol. Oncol., 25, 187 Pavelic, 2007, Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma, Gynecol. Oncol., 105, 727, 10.1016/j.ygyno.2007.02.012 Attias-Geva, 2011, Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines, Gynecol. Oncol., 121, 383, 10.1016/j.ygyno.2011.01.008 King, 2012, Insulin-like growth factor: current concepts and new developments in cancer therapy, Recent Pat. Anticancer Drug Discov., 7, 14, 10.2174/157489212798357930 Broussas, 2009, Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor, Int. J. Cancer, 124, 2281, 10.1002/ijc.24186 Pandini, 2007, Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors, Eur. J. Cancer., 43, 1318, 10.1016/j.ejca.2007.03.009 Cao, 2008, Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody, Cancer Res., 68, 8039, 10.1158/0008-5472.CAN-08-1712 Sehat, 2010, SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor, Science Signaling, 3, 10.1126/scisignal.2000628 Baserga, 2013, The decline and fall of the IGF-I receptor, J. Cell Physiol., 228, 675, 10.1002/jcp.24217 Hailey, 2002, Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells, Mol. Cancer. Ther., 1, 1349 Maloney, 2003, An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation, Cancer Res., 63, 5073 Fagan, 2012, Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment, Cancer Res., 72, 3372, 10.1158/0008-5472.CAN-12-0684 Olmos, 2011, Targeting the insulin-like growth factor 1 receptor in ewing’s sarcoma: reality and expectations, Sarcoma, 2011, 402508, 10.1155/2011/402508 Gualberto, 2011, Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab, Br. J. Cancer, 104, 68, 10.1038/sj.bjc.6605972 de Bono, 2007, Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor, Clin. Cancer Res., 13, 3611, 10.1158/1078-0432.CCR-07-0268 Asmane, 2012, Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas, Eur. J. Cancer, 10.1016/j.ejca.2012.05.009 Pollak, 2012, The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology, Clin. Cancer Res., 18, 40, 10.1158/1078-0432.CCR-11-0998